Burlington, MA-based medical device developer InfraReDx announced today that it had raised $24.1 million in an equity offering it sold to existing investors. The money will go to ongoing and new clinical trials exploring additional applications of its LipiScan IVUS coronary imaging system, which combines near infrared light and a type of intravascular ultrasound to provide detailed images of a type of fatty plaque in the arteries. Last October InfraReDx raised $21 million to launch the system in the U.S. shortly after it had gained FDA clearance.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
